{"drugs":["Avelox","Avelox I.V.","Moxeza","Moxifloxacin Hydrochloride","Vigamox"],"mono":[{"id":"925060-s-0","title":"Generic Names","mono":"Moxifloxacin Hydrochloride"},{"id":"925060-s-1","title":"Dosing and Indications","sub":[{"id":"925060-s-1-4","title":"Adult Dosing","mono":"<ul><li>When administering via IV infusion, do not exceed the recommended dose or infusion rate to avoid risk of QT prolongation.<\/li><li>May switch from IV to oral administration without dose adjustment.<\/li><li><b>Acute infective exacerbation of chronic obstructive pulmonary disease:<\/b> 400 mg ORALLY or IV infusion over 60 minutes once every 24 hours for 5 days<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution (Moxeza(TM)) 1 drop to affected eye(s) 2 times a day for 7 days<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution (Vigamox(R)) 1 drop to affected eye(s) 3 times a day for 7 days  or<\/li><li><b>Bacterial sinusitis, acute:<\/b> 400 mg ORALLY or IV infusion over 60 minutes every 24 hours for 10 days (manufacturer dose)<\/li><li><b>Bacterial sinusitis, acute:<\/b> (Second-line) 400 mg ORALLY or IV once daily (guideline dose)<\/li><li><b>Community acquired pneumonia:<\/b> 400 mg ORALLY or IV infusion over 60 minutes once every 24 hours for 7 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 400 mg ORALLY or IV infusion over 60 minutes every 24 hours for 7 to 21 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated:<\/b> 400 mg ORALLY or IV infusion over 60 minutes every 24 hours for 7 days<\/li><li><b>Infectious disease of abdomen, Complicated:<\/b>  400 mg ORALLY or IV infusion over 60 minutes once every 24 hours for 5 to 14 days<\/li><li><b>Plague; Treatment and Prophylaxis:<\/b> 400 mg ORALLY or IV infusion over 60 minutes once every 24 hours for 10 to 14 days; initiate as soon as possible following suspected or confirmed exposure.<\/li><\/ul>"},{"id":"925060-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy of oral and IV moxifloxacin have not been established in pediatric patients.<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution (Moxeza(TM)); 4 months and older) 1 drop to affected eye(s) 2 times a day for 7 days<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution (Vigamox(R)); 1 year of age and older) 1 drop to affected eye(s) 3 times a day for 7 days<\/li><\/ul>"},{"id":"925060-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dose adjustment is necessary for patients with renal impairment<\/li><li><b>hepatic impairment:<\/b> no dose adjustment recommended for mild, moderate, or severe hepatic insufficiency (Child Pugh Classes A, B, or C); use caution as metabolic alterations associated with hepatic impairment may lead to QT prolongation<\/li><li><b>geriatric:<\/b> no dosage adjustment is necessary<\/li><li><b>hemodialysis, peritoneal dialysis:<\/b> no dosage adjustment is necessary<\/li><\/ul>"},{"id":"925060-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute infective exacerbation of chronic obstructive pulmonary disease<\/li><li>Bacterial conjunctivitis<\/li><li>Bacterial sinusitis, acute<\/li><li>Community acquired pneumonia<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Complicated<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated<\/li><li>Infectious disease of abdomen, Complicated<\/li><li>Plague; Treatment and Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Tuberculosis<br\/>"}]},{"id":"925060-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Solution)<\/b><br\/>Fluoroquinolones, including moxifloxacin hydrochloride, are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.<br\/><\/li><li><b>Oral (Tablet)<\/b><br\/>Fluoroquinolones, including moxifloxacin hydrochloride, are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.<br\/><\/li><\/ul>"},{"id":"925060-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925060-s-3-9","title":"Contraindications","mono":"Hypersensitivity to moxifloxacin or any quinolone antibiotic <br\/>"},{"id":"925060-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>--Tendinitis and tendon rupture may occur during or after completion of therapy; increased risk with age over 60 years, concomitant steroid therapy, kidney, heart, or lung transplant, strenuous physical activity, renal failure, and previous tendon disorders; discontinue use if suspected<\/li><li>-- May exacerbate muscle weakness in patients with myasthenia gravis; ventilatory support requirement and death have been reported; avoid use<\/li><li>Cardiovascular:<\/li><li>--QT-interval prolongation has been reported; avoid use in patients with known QT prolongation, uncorrected hypokalemia or hypomagnesemia, ventricular arrhythmias, or in patients receiving concurrent Class IA or III antiarrhythmics, or other drugs that prolong the QT interval<\/li><li>-- Risk for QT prolongation may increase with increasing plasma concentrations or infusion rates, and in patients with proarrhythmic conditions, cirrhosis, or receiving other drugs known to prolong QT interval; avoid exceeding recommended dose or infusion rate<\/li><li>-- Metabolic disturbances associated with liver cirrhosis may lead to QT interval prolongation; ECG monitoring recommended<\/li><li>-- Vasculitis has been reported<\/li><li>Dermatologic:<\/li><li>-- Serious dermatological reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome) have been reported; discontinue use at first sign of rash<\/li><li>-- Phototoxicity may occur with exposure to sunlight or UV light; discontinue use if occurs<\/li><li>Endocrine\/Metabolic:<\/li><li>-- Blood glucose disturbances including hypoglycemia and hyperglycemia have been reported; increased risk in elderly diabetic patients who had concomitant treatment with an oral hypoglycemic agent or insulin; monitoring recommended and discontinuation may be necessary<\/li><li>Hematologic:<\/li><li>-- Hematologic reactions, including hemolytic and aplastic anemia, thrombotic thrombocytopenic purpura, and agranulocytosis, have been reported<\/li><li>Hepatic:<\/li><li>-- Hypersensitivity reactions, serious, including anaphylaxis, have been reported; discontinue use at first sign<\/li><li>-- Hepatitis, jaundice, and acute hepatic necrosis or failure have been reported; discontinue use at first sign of jaundice<\/li><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea, including mild diarrhea to fatal colitis, has been reported<\/li><li>Neurologic:<\/li><li>-- CNS events including nervousness, agitation, insomnia, anxiety, nightmares, or paranoia may occur<\/li><li>-- Convulsions, increased intracranial pressure (eg, pseudotumor cerebri), and CNS events (eg, tremors, hallucinations, suicidal thoughts) may occur; discontinue use<\/li><li>-- CNS disorders (eg, severe cerebral arteriosclerosis, epilepsy) and conditions that lower the seizure threshold; increased risk for CNS events and seizures<\/li><li>-- Polyneuropathy, resulting in paresthesias, hypoesthesias, dysesthesias, and weakness, has been reported; may occur soon after initiation and be irreversible; discontinue use if symptoms occur<\/li><li>Ophthalmic:<\/li><li>-- Avoid wearing contact lenses during moxifloxacin ophthalmic solution use if signs or symptoms of bacterial conjunctivitis are present<\/li><li>Renal:<\/li><li>-- Interstitial nephritis and acute renal insufficiency or failure have been reported<\/li><li>Respiratory:<\/li><li>-- Allergic pneumonitis has been reported; discontinue use at first sign of hypersensitivity<\/li><li>Concomitant Use:<\/li><li>-- Concomitant use with Class IA (eg, procainamide, quinidine) or Class III (eg, amiodarone, sotalol) antiarrhythmic agents should be avoided<\/li><\/ul>"},{"id":"925060-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Moxifloxacin: C (FDA)<\/li><li>Moxifloxacin: B3 (AUS)<\/li><\/ul>"},{"id":"925060-s-3-12","title":"Breast Feeding","mono":"Moxifloxacin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"925060-s-4","title":"Drug Interactions","sub":[{"id":"925060-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"925060-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Acetohexamide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Benfluorex (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gliclazide (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Gliquidone (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rasagiline (established)<\/li><li>Repaglinide (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><li>Warfarin (established)<\/li><\/ul>"},{"id":"925060-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (probable)<\/li><li>Aluminum Hydroxide (probable)<\/li><li>Aluminum Phosphate (probable)<\/li><li>Betamethasone (established)<\/li><li>Budesonide (established)<\/li><li>Corticotropin (established)<\/li><li>Cortisone (established)<\/li><li>Cosyntropin (established)<\/li><li>Deflazacort (established)<\/li><li>Dexamethasone (established)<\/li><li>Didanosine (probable)<\/li><li>Dihydroxyaluminum Aminoacetate (probable)<\/li><li>Dihydroxyaluminum Sodium Carbonate (probable)<\/li><li>Fludrocortisone (established)<\/li><li>Fluocortolone (established)<\/li><li>Hydrocortisone (established)<\/li><li>Iron (probable)<\/li><li>Lanthanum Carbonate (probable)<\/li><li>Magaldrate (probable)<\/li><li>Magnesium Carbonate (probable)<\/li><li>Magnesium Hydroxide (probable)<\/li><li>Magnesium Oxide (probable)<\/li><li>Magnesium Trisilicate (probable)<\/li><li>Methylprednisolone (established)<\/li><li>Prednisolone (established)<\/li><li>Prednisone (established)<\/li><li>Rifampin (established)<\/li><li>Sucralfate (probable)<\/li><li>Triamcinolone (established)<\/li><li>Zinc (probable)<\/li><\/ul>"}]},{"id":"925060-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypokalemia (1%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (2%), Constipation (2%), Diarrhea (6%), Nausea (7%), Vomiting (2%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level abnormal (1%)<\/li><li><b>Neurologic:<\/b>Dizziness (3%), Headache (4%)<\/li><li><b>Ophthalmic:<\/b>Dry eyes (Ophthalmic, 1% to 6%), Keratitis (Ophthalmic, 1% to 6%), Pain in eye (Ophthalmic, 1% to 6%), Reduced visual acuity (Ophthalmic, 1% to 6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (Oral\/IV, 0.1% to less than 1%), Torsades de pointes<\/li><li><b>Dermatologic:<\/b>Rash (Oral\/IV, 0.1% to less than 1%), Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Endocrine metabolic:<\/b>Hyperglycemia (Oral\/IV, 0.1% to less than 1%), Hypoglycemia<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia, Pancytopenia, Thrombocytopenia (Oral\/IV, 0.1% to less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatitis, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Myasthenia gravis, Exacerbation, Rupture of tendon, Tendinitis<\/li><li><b>Neurologic:<\/b>Peripheral neuropathy, Seizure<\/li><li><b>Ophthalmic:<\/b>Retinal detachment<\/li><li><b>Renal:<\/b>Renal failure (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Extrinsic allergic alveolitis<\/li><li><b>Other:<\/b>Serum sickness due to drug<\/li><\/ul>"},{"id":"925060-s-6","title":"Drug Name Info","sub":{"0":{"id":"925060-s-6-17","title":"US Trade Names","mono":"<ul><li>Avelox<\/li><li>Avelox I.V.<\/li><li>Vigamox<\/li><li>Moxeza<\/li><\/ul>"},"2":{"id":"925060-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Fluoroquinolone<\/li><\/ul>"},"3":{"id":"925060-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925060-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"925060-s-7","title":"Mechanism Of Action","mono":"Moxifloxacin hydrochloride is a fluoroquinolone antibiotic that inhibits topoisomerases II and IV, which control DNA topology and assist in DNA replication, repair and transcription. It has activity against a wide range of aerobic gram-positive and gram-negative microorganisms.<br\/>"},{"id":"925060-s-8","title":"Pharmacokinetics","sub":[{"id":"925060-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.5 to 3 hr.<\/li><li>Bioavailability, Oral: approximately 90%<\/li><li>Effect of food: no effect on absorption<\/li><\/ul>"},{"id":"925060-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 1.7 L\/kg to 2.7 L\/kg<\/li><li>Vd: intravenous, severe hepatic impairment, 104.3 to 154.1 L<\/li><li>Protein binding: approximately 30% to 50%<\/li><\/ul>"},{"id":"925060-s-8-25","title":"Metabolism","mono":"Hepatic: 52% via glucuronide and sulfate conjugation; CYP450 independent <br\/>"},{"id":"925060-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: approximately 25% unchanged<\/li><li>Renal: approximately 20% unchanged<\/li><li>Dialyzable: Yes (hemodialysis), 9%; Yes (peritoneal dialysis), 3%<\/li><\/ul>"},{"id":"925060-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV, healthy adults: 10.1 +\/- 1.6 hr to 14.8 +\/- 2.2 hr<\/li><li>Oral, healthy adults: 12.7 +\/- 1.9 hr<\/li><li>Ophthalmic: 13 hr<\/li><\/ul>"}]},{"id":"925060-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>Administer only by IV infusion; do not give by intra-arterial, IM, intrathecal, intraperitoneal, or subQ injection.<\/li><li>Do not mix or infuse simultaneously with other drugs or additives.<\/li><li>Flush IV line before and after infusion.<\/li><li>IV solution in ready-to-use 250 mL flexibags in 0.8% sodium chloride is yellow.<\/li><li>Administer by IV infusion over 60 minutes by direct infusion or via a Y-site IV infusion set already in place. Avoid a rapid or bolus IV infusion.<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>Give with or without food, with a generous amount of fluid.<\/li><li>Administer at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron, or zinc, including antacids, sucralfate, multivitamins, and didanosine-buffered tablets for oral suspension or powder for oral solution.<\/li><\/ul><\/li><\/ul>"},{"id":"925060-s-10","title":"Monitoring","mono":"<ul><li>Resolution of infection indicates efficacy.<\/li><li>Blood glucose; in diabetic patients<\/li><li>ECG; in patients with liver cirrhosis<\/li><\/ul>"},{"id":"925060-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 400 MG<br\/><\/li><li><b>Avelox I.V.<\/b><br\/>Intravenous Solution: 400 MG\/250 ML<br\/><\/li><li><b>Avelox<\/b><br\/>Oral Tablet: 400 MG<br\/><\/li><li><b>Moxeza<\/b><br\/>Ophthalmic Solution: 0.5 %<br\/><\/li><li><b>Vigamox<\/b><br\/>Ophthalmic Solution: 0.5 %<br\/><\/li><\/ul>"},{"id":"925060-s-12","title":"Toxicology","sub":[{"id":"925060-s-12-31","title":"Clinical Effects","mono":"<b>FLUOROQUINOLONES<\/b><br\/>USES: Fluoroquinolones are bacteriocidal broad spectrum antibiotics. PHARMACOLOGY: Fluoroquinolones inhibit bacterial topoisomerase IV and DNA gyrase enzymes required for DNA replication, transcription, repair and recombination. EPIDEMIOLOGY: Overdose is rare. OVERDOSE: Dizziness, drowsiness, disorientation, slurred speech, nausea and vomiting. ADVERSE EFFECTS: Nausea\/vomiting, diarrhea, headache, drowsiness, and insomnia. Seizures, hallucinations, elevated liver enzymes and renal toxicity are rare. Seizures appear related to predisposing factors. Hypersensitivity reactions including anaphylaxis and vasculitis have developed. WITHDRAWAL FROM MARKET: Grepafloxacin was withdrawn from the worldwide market in October, 1999 after reports of cardiovascular toxicity; QT prolongation had been associated with its use. Gatifloxacin was voluntarily withdrawn from the market in May 2006 due to reports of severe hypo- and hyperglycemic events. <br\/>"},{"id":"925060-s-12-32","title":"Treatment","mono":"<b>FLUOROQUINOLONES <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal, gastric lavage<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Monitoring of patient: Monitor liver enzymes and renal function with significant overdose.  Monitor fluid &amp; electrolyte status if severe GI effects; CNS function.<\/li><\/ul>"},{"id":"925060-s-12-33","title":"Range of Toxicity","mono":"<b>FLUOROQUINOLONES<\/b><br\/>Unknown.  Recommended dose (adults):  300-500 mg BID; contraindicated in children. <br\/>"}]},{"id":"925060-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to wear protective clothing, use sunscreen, avoid tanning beds, and avoid excessive exposure to sunlight.<\/li><li>Counsel patient to avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness or lightheadedness.<\/li><li>Tell patient to report symptoms of peripheral neuropathy or pain, inflammation, or rupture of a tendon.<\/li><li>Side effects may include diarrhea, vomiting, constipation, fever, headache, or insomnia.<\/li><li>Instruct patient to report symptoms of QTc prolongation.<\/li><li>Advise diabetic patient to monitor for hyperglycemia or hypoglycemia and to report difficulties with glycemic control.<\/li><li>Instruct patient to take drug at least 4 hours before or 8 hours after products containing iron, zinc, magnesium, or aluminum.<\/li><li>Instruct patient to take a missed dose as soon as possible but not to take more than one dose per day.<\/li><\/ul>"}]}